RESEARCH REPORT
Thermo Fisher Scientific Inc
TMO
$697.00
As of 2026-11-01
Research note — 2026-11-01. Educational analysis, not financial advice.
The one-line version
Thermo Fisher Scientific Inc trades near $697.00 on a trailing multiple of about 36.8x versus its own 5-year median near 30.5x, against contested Street targets and the usual concentration and execution risks. That's the tension. Everything below is the detail.
That's the tension. Everything below is the detail.
1. What you're paying
| Now | Its own 5-year median | Gap | |
|---|---|---|---|
| P/E (trailing) | ~36.8 | ~30.5 | +21% |
| P/E (forward) | ~25.1 | — | — |
| EPS (TTM) | 18.96 | — | — |
| Gross margin | 41.2% | — | — |
What that means in plain terms: the gap versus the company's own history is the growth or durability the market is already pricing. It is not automatically wrong — it is the bet.
Fair-value anchors on file:
- 5-year median P/E multiple: $577.86 — Applies the 5-year median multiple (30.5x) to trailing EPS.
- Street mean target: $752.12 — Average published analyst target.
- Street target midpoint: $710.00 — Midpoint of $590.00–$830.00 published range.
Street targets run from $590.00 to $830.00. A wide spread means the name is contested, not consensus.
2. What the bulls are counting on
- Thermo Fisher Scientific (TMO) Stock Fair Value Rises After Q3 Beat And Higher Guidance
- Benzinga's 'Stock Whisper' Index: Five Stocks market participants Secretly Monitor But Don't Talk About Yet
- How market participants Are Reacting To Thermo Fisher Scientific Stock After Strong Q3 Earnings
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
3. What the bears see
- Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGEN
- Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AI
- Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and Roche
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
4. What would have to be true
For the stock to justify ~36.8x rather than its 5-year ~30.5x, roughly all of the following need to neutral:
- Growth or margin durability shows up in the next several reports, not just in narrative.
- Key revenue concentrations survive competitive and regulatory pressure.
- Execution on the current product or services cycle stays on schedule.
- The Street target range compresses as results clarify the contested assumptions.
Ask yourself honestly: how many of those would you bet on individually? Multiply your answers together.
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
5. What to watch next
- Next earnings date: 2027-01-27
- Trailing and forward multiples versus the company's own history
- Segment growth rates in the next 10-Q / earnings release
- Material Form 4 and 13F changes
- Whether the Street high-to-low target spread narrows or widens
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
6. What this note does not do
It doesn't tell you to buy or sell. It won't, ever.
You have the valuation in context, the strongest version of both cases, and the specific assumptions the current price depends on. What you do with that depends on your time horizon, your existing exposure, your risk tolerance, and what else you could do with the money — none of which we know.
If you want someone to tell you what to do, you want a licensed financial adviser, and that is a genuinely reasonable thing to want.
Educational and informational purposes only. Not investment advice and not a recommendation to buy or sell any security. GetStockReport is not a registered investment adviser. Figures are as of 2026-11-01 and go stale quickly — verify against primary sources before acting. All investments carry risk including loss of principal. Past performance does not guarantee future results.
8. Analyst ratings & targets
No recent activity
Analyst opinions change frequently. Past upgrades do not predict future returns.
9. Important news
Nov 4, 2026|Guidance Up, Trend Intact: Mettler-Toledo Is Today's Double-Confirmation Stock(Yahoo)
For questions about this article or underlying research, email help@trefis.com.
Dublin, Nov. 04, 2026 (GLOBE NEWSWIRE) -- "Microarray Analysis - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global microarray analysis market was valued at US$3.3 billion in 2025 and is projected to reach US$5.1 billion by 2032, expanding at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Market growth is supported by expanding genomics research, rising demand for personalized medicine, increased use of molecular diagn
Nov 4, 2026|Microcarriers - Global Strategic Business Report 2026: Secure Your Share of $3.9 Billion by 2032 | Benchmark Corning, Danaher, Sartorius, and Thermo Fisher(Yahoo)
Dublin, Nov. 04, 2026 (GLOBE NEWSWIRE) -- "Microcarriers - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global microcarriers market was valued at US$2.3 billion in 2025 and is projected to reach US$3.9 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.5%. Market growth is supported by increasing biologics production, advances in cell and gene therapy, expanding vaccine manufacturing capacity, and sustained investment in biotechn
Nov 4, 2026|Thermo Fisher (TMO) Emerges as Top Contributor After 27% Quarterly Gain(Yahoo)
BUFFALO Funds, an actively managed mutual fund advised by Kornitzer Capital Management, released its third-quarter 2026 investor letter for “Buffalo Growth Fund”. The letter can be downloaded here. The Buffalo Growth Fund advanced 4.57% in Q3, significantly outperforming the Russell 3000® Growth Index’s 0.45%. The primary driver of this outperformance was stock selection in Information […]
Boost R&D ROI with high-throughput automation, 3D cell cultures, label-free detection and AI—accelerating drug screening, improving accuracy and reducing development costs.Dublin, Nov. 04, 2026 (GLOBE NEWSWIRE) -- "Cell Based Assays - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global cell-based assays market was valued at US$17.9 billion in 2025 and is projected to reach US$30.5 billion by 2032, expanding at a compound annual growth rate (CAGR
News headlines are reported as-is. Verify important claims with original sources.
10. Insider Form 4 activity
| Date | Executive | Action | Shares | Value |
|---|---|---|---|---|
| Oct 28, 2026 | SPERLING SCOTT M | Sell | 3,490 | $0 |
| Oct 28, 2026 | Britt Lisa P. (Sr. VP and Chief HR Officer) | Sell | 2,831 | $2.0M |
Form 4 filings are routine transactions. Scheduled sales (10b5-1 plans) are normal and not signals.
11. Institutional 13F holdings
| Fund | Shares | Position | Change |
|---|---|---|---|
| Vanguard Group | 30,425,604 | $17.6B | — |
| State Street | 16,825,879 | $8.4B | — |
| BlackRock | 8,666,318 | $4.8B | — |
| BlackRock Institutional Trust | 616,250 | $87.0M | — |
These are 45-day lagged filings (SEC requirement). Position changes happened in the past.
12. Earnings this week
No recent activity
Earnings dates are estimates and may shift. EPS estimates are consensus, not predictions.